Interleukin -37 in rheumatoid arthritis: Correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq

The contribution of anti-inflammatory cytokines to rheumatoid arthritis (RA) is not fully comprehended. In the current research we assessed the serum concentration of interleukin (IL)-37 anti-inflammatory cytokine in RA, studied its association to disease activity score 28 (DAS28) and investigated s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Egyptian journal of immunology 2023-04, Vol.30 (2), p.162-173
Hauptverfasser: Al-Tae, Firas M D, Al-Harbi, Ahmed A, Turki, Khalid W, Sood, Muna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173
container_issue 2
container_start_page 162
container_title The Egyptian journal of immunology
container_volume 30
creator Al-Tae, Firas M D
Al-Harbi, Ahmed A
Turki, Khalid W
Sood, Muna
description The contribution of anti-inflammatory cytokines to rheumatoid arthritis (RA) is not fully comprehended. In the current research we assessed the serum concentration of interleukin (IL)-37 anti-inflammatory cytokine in RA, studied its association to disease activity score 28 (DAS28) and investigated single nucleotide polymorphism (rs2723176) of IL-37 gene as a threat for RA development. The case-control study included 60 RA patients and 30 normal control individuals. Serum IL-37 was assessed by ELISA and genotyped by "sequence-specific primer-polymerase chain reaction (SSP-PCR)". The mean IL-37 was elevated in RA patients (69.42 ng /l ± 62.99) compared to control individuals (14.66 ng /l ± 23.58, p < 0.001). IL-37 tended to increase with age where highest levels were noted in patients more than 60 years (p = 0.037). No Gender influence was found on IL-37 level (p>0.05). At best cut-off value of 31.5 ng/ l, IL-37 had a sensitivity of 73.3% and specificity of 83.3%. No correlation of IL-37 with DAS 28 score was observed (r=0.1497, p=0.2535). For IL-37 (rs2723176) gene polymorphism, C/C genotype was prevailing in both RA (90%) and normal controls (93.3%) compared to A/C or A/A. Also, no variation was found between patents and controls in regard to C/C genotype (OR = 0.643, 95% CI (0.122-3.39, p=0.603). The mean IL-37 concentration in RA patients with C/C genotype (59.70± 67.92) was not different from AC genotype (80.54± 94.18, p=0.4748). We concluded that serum IL-37 had the implication as a diagnostic marker in RA. However, it did not correlate with clinical severity of the disease. Meanwhile, IL-37 (rs2723176) gene polymorphism did not seem to be as a risk factor for RA, nor contributed to the increase of IL-37 level among patients.
doi_str_mv 10.55133/eji.300215
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2799172877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2799172877</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2415-a684309b7e83b6e67f3c2d9c17f3a889649b0fb27eac68940de7e0b055a029d63</originalsourceid><addsrcrecordid>eNpNkDtPwzAYRS0EolXpxI48IkGKH0kcs6GKR6UiFpgjx_lCXJy4tRNQ_j2BAmK6dzg6w0HolJJFklDOr2BjFpwQRpMDNKWUkiiWhB3--xM0D2FDCKEsEakQx2jCBeE0TpMpGlZtB95C_2ZaHHGBx_E19I3qnCmx8l3tTWfCNV4678GqzrgWf5iuxtqa1mhlcYB3GKEBq7bEr9BCZzTeOjs0zm9rE5rwZX10obdYj9wlXnm1O0FHlbIB5j87Qy93t8_Lh2j9dL9a3qwjzWKaRCrNYk5kISDjRQqpqLhmpdR0PCrLZBrLglQFE6B0msmYlCCAFCRJFGGyTPkMne-9W-92PYQub0zQYK1qwfUhZ0JKKlgmxIhe7FHtXQgeqnzrTaP8kFOSf-fOx9z5PvdIn_2I-6KB8o_9jcs_Ab8ce7E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799172877</pqid></control><display><type>article</type><title>Interleukin -37 in rheumatoid arthritis: Correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Al-Tae, Firas M D ; Al-Harbi, Ahmed A ; Turki, Khalid W ; Sood, Muna</creator><creatorcontrib>Al-Tae, Firas M D ; Al-Harbi, Ahmed A ; Turki, Khalid W ; Sood, Muna ; Department of Microbiology, College of Medicine, University of Mosul, Mosul, Iraq</creatorcontrib><description>The contribution of anti-inflammatory cytokines to rheumatoid arthritis (RA) is not fully comprehended. In the current research we assessed the serum concentration of interleukin (IL)-37 anti-inflammatory cytokine in RA, studied its association to disease activity score 28 (DAS28) and investigated single nucleotide polymorphism (rs2723176) of IL-37 gene as a threat for RA development. The case-control study included 60 RA patients and 30 normal control individuals. Serum IL-37 was assessed by ELISA and genotyped by "sequence-specific primer-polymerase chain reaction (SSP-PCR)". The mean IL-37 was elevated in RA patients (69.42 ng /l ± 62.99) compared to control individuals (14.66 ng /l ± 23.58, p &lt; 0.001). IL-37 tended to increase with age where highest levels were noted in patients more than 60 years (p = 0.037). No Gender influence was found on IL-37 level (p&gt;0.05). At best cut-off value of 31.5 ng/ l, IL-37 had a sensitivity of 73.3% and specificity of 83.3%. No correlation of IL-37 with DAS 28 score was observed (r=0.1497, p=0.2535). For IL-37 (rs2723176) gene polymorphism, C/C genotype was prevailing in both RA (90%) and normal controls (93.3%) compared to A/C or A/A. Also, no variation was found between patents and controls in regard to C/C genotype (OR = 0.643, 95% CI (0.122-3.39, p=0.603). The mean IL-37 concentration in RA patients with C/C genotype (59.70± 67.92) was not different from AC genotype (80.54± 94.18, p=0.4748). We concluded that serum IL-37 had the implication as a diagnostic marker in RA. However, it did not correlate with clinical severity of the disease. Meanwhile, IL-37 (rs2723176) gene polymorphism did not seem to be as a risk factor for RA, nor contributed to the increase of IL-37 level among patients.</description><identifier>ISSN: 1110-4902</identifier><identifier>EISSN: 1110-4902</identifier><identifier>DOI: 10.55133/eji.300215</identifier><identifier>PMID: 37031465</identifier><language>eng</language><publisher>Egypt</publisher><subject>Arthritis, Rheumatoid ; Case-Control Studies ; Cytokines - genetics ; Genetic Predisposition to Disease ; Genotype ; Humans ; Interleukins ; Iraq ; Middle Aged ; Polymorphism, Single Nucleotide</subject><ispartof>The Egyptian journal of immunology, 2023-04, Vol.30 (2), p.162-173</ispartof><rights>Copyright© by the Egyptian Association of Immunologists.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2415-a684309b7e83b6e67f3c2d9c17f3a889649b0fb27eac68940de7e0b055a029d63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37031465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Tae, Firas M D</creatorcontrib><creatorcontrib>Al-Harbi, Ahmed A</creatorcontrib><creatorcontrib>Turki, Khalid W</creatorcontrib><creatorcontrib>Sood, Muna</creatorcontrib><creatorcontrib>Department of Microbiology, College of Medicine, University of Mosul, Mosul, Iraq</creatorcontrib><title>Interleukin -37 in rheumatoid arthritis: Correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq</title><title>The Egyptian journal of immunology</title><addtitle>Egypt J Immunol</addtitle><description>The contribution of anti-inflammatory cytokines to rheumatoid arthritis (RA) is not fully comprehended. In the current research we assessed the serum concentration of interleukin (IL)-37 anti-inflammatory cytokine in RA, studied its association to disease activity score 28 (DAS28) and investigated single nucleotide polymorphism (rs2723176) of IL-37 gene as a threat for RA development. The case-control study included 60 RA patients and 30 normal control individuals. Serum IL-37 was assessed by ELISA and genotyped by "sequence-specific primer-polymerase chain reaction (SSP-PCR)". The mean IL-37 was elevated in RA patients (69.42 ng /l ± 62.99) compared to control individuals (14.66 ng /l ± 23.58, p &lt; 0.001). IL-37 tended to increase with age where highest levels were noted in patients more than 60 years (p = 0.037). No Gender influence was found on IL-37 level (p&gt;0.05). At best cut-off value of 31.5 ng/ l, IL-37 had a sensitivity of 73.3% and specificity of 83.3%. No correlation of IL-37 with DAS 28 score was observed (r=0.1497, p=0.2535). For IL-37 (rs2723176) gene polymorphism, C/C genotype was prevailing in both RA (90%) and normal controls (93.3%) compared to A/C or A/A. Also, no variation was found between patents and controls in regard to C/C genotype (OR = 0.643, 95% CI (0.122-3.39, p=0.603). The mean IL-37 concentration in RA patients with C/C genotype (59.70± 67.92) was not different from AC genotype (80.54± 94.18, p=0.4748). We concluded that serum IL-37 had the implication as a diagnostic marker in RA. However, it did not correlate with clinical severity of the disease. Meanwhile, IL-37 (rs2723176) gene polymorphism did not seem to be as a risk factor for RA, nor contributed to the increase of IL-37 level among patients.</description><subject>Arthritis, Rheumatoid</subject><subject>Case-Control Studies</subject><subject>Cytokines - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Humans</subject><subject>Interleukins</subject><subject>Iraq</subject><subject>Middle Aged</subject><subject>Polymorphism, Single Nucleotide</subject><issn>1110-4902</issn><issn>1110-4902</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkDtPwzAYRS0EolXpxI48IkGKH0kcs6GKR6UiFpgjx_lCXJy4tRNQ_j2BAmK6dzg6w0HolJJFklDOr2BjFpwQRpMDNKWUkiiWhB3--xM0D2FDCKEsEakQx2jCBeE0TpMpGlZtB95C_2ZaHHGBx_E19I3qnCmx8l3tTWfCNV4678GqzrgWf5iuxtqa1mhlcYB3GKEBq7bEr9BCZzTeOjs0zm9rE5rwZX10obdYj9wlXnm1O0FHlbIB5j87Qy93t8_Lh2j9dL9a3qwjzWKaRCrNYk5kISDjRQqpqLhmpdR0PCrLZBrLglQFE6B0msmYlCCAFCRJFGGyTPkMne-9W-92PYQub0zQYK1qwfUhZ0JKKlgmxIhe7FHtXQgeqnzrTaP8kFOSf-fOx9z5PvdIn_2I-6KB8o_9jcs_Ab8ce7E</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Al-Tae, Firas M D</creator><creator>Al-Harbi, Ahmed A</creator><creator>Turki, Khalid W</creator><creator>Sood, Muna</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202304</creationdate><title>Interleukin -37 in rheumatoid arthritis: Correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq</title><author>Al-Tae, Firas M D ; Al-Harbi, Ahmed A ; Turki, Khalid W ; Sood, Muna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2415-a684309b7e83b6e67f3c2d9c17f3a889649b0fb27eac68940de7e0b055a029d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Arthritis, Rheumatoid</topic><topic>Case-Control Studies</topic><topic>Cytokines - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Humans</topic><topic>Interleukins</topic><topic>Iraq</topic><topic>Middle Aged</topic><topic>Polymorphism, Single Nucleotide</topic><toplevel>online_resources</toplevel><creatorcontrib>Al-Tae, Firas M D</creatorcontrib><creatorcontrib>Al-Harbi, Ahmed A</creatorcontrib><creatorcontrib>Turki, Khalid W</creatorcontrib><creatorcontrib>Sood, Muna</creatorcontrib><creatorcontrib>Department of Microbiology, College of Medicine, University of Mosul, Mosul, Iraq</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Egyptian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Tae, Firas M D</au><au>Al-Harbi, Ahmed A</au><au>Turki, Khalid W</au><au>Sood, Muna</au><aucorp>Department of Microbiology, College of Medicine, University of Mosul, Mosul, Iraq</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin -37 in rheumatoid arthritis: Correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq</atitle><jtitle>The Egyptian journal of immunology</jtitle><addtitle>Egypt J Immunol</addtitle><date>2023-04</date><risdate>2023</risdate><volume>30</volume><issue>2</issue><spage>162</spage><epage>173</epage><pages>162-173</pages><issn>1110-4902</issn><eissn>1110-4902</eissn><abstract>The contribution of anti-inflammatory cytokines to rheumatoid arthritis (RA) is not fully comprehended. In the current research we assessed the serum concentration of interleukin (IL)-37 anti-inflammatory cytokine in RA, studied its association to disease activity score 28 (DAS28) and investigated single nucleotide polymorphism (rs2723176) of IL-37 gene as a threat for RA development. The case-control study included 60 RA patients and 30 normal control individuals. Serum IL-37 was assessed by ELISA and genotyped by "sequence-specific primer-polymerase chain reaction (SSP-PCR)". The mean IL-37 was elevated in RA patients (69.42 ng /l ± 62.99) compared to control individuals (14.66 ng /l ± 23.58, p &lt; 0.001). IL-37 tended to increase with age where highest levels were noted in patients more than 60 years (p = 0.037). No Gender influence was found on IL-37 level (p&gt;0.05). At best cut-off value of 31.5 ng/ l, IL-37 had a sensitivity of 73.3% and specificity of 83.3%. No correlation of IL-37 with DAS 28 score was observed (r=0.1497, p=0.2535). For IL-37 (rs2723176) gene polymorphism, C/C genotype was prevailing in both RA (90%) and normal controls (93.3%) compared to A/C or A/A. Also, no variation was found between patents and controls in regard to C/C genotype (OR = 0.643, 95% CI (0.122-3.39, p=0.603). The mean IL-37 concentration in RA patients with C/C genotype (59.70± 67.92) was not different from AC genotype (80.54± 94.18, p=0.4748). We concluded that serum IL-37 had the implication as a diagnostic marker in RA. However, it did not correlate with clinical severity of the disease. Meanwhile, IL-37 (rs2723176) gene polymorphism did not seem to be as a risk factor for RA, nor contributed to the increase of IL-37 level among patients.</abstract><cop>Egypt</cop><pmid>37031465</pmid><doi>10.55133/eji.300215</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1110-4902
ispartof The Egyptian journal of immunology, 2023-04, Vol.30 (2), p.162-173
issn 1110-4902
1110-4902
language eng
recordid cdi_proquest_miscellaneous_2799172877
source MEDLINE; Alma/SFX Local Collection
subjects Arthritis, Rheumatoid
Case-Control Studies
Cytokines - genetics
Genetic Predisposition to Disease
Genotype
Humans
Interleukins
Iraq
Middle Aged
Polymorphism, Single Nucleotide
title Interleukin -37 in rheumatoid arthritis: Correlation with clinical severity and genetic polymorphisms in Mosul city, Iraq
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T05%3A46%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin%20-37%20in%20rheumatoid%20arthritis:%20Correlation%20with%20clinical%20severity%20and%20genetic%20polymorphisms%20in%20Mosul%20city,%20Iraq&rft.jtitle=The%20Egyptian%20journal%20of%20immunology&rft.au=Al-Tae,%20Firas%20M%20D&rft.aucorp=Department%20of%20Microbiology,%20College%20of%20Medicine,%20University%20of%20Mosul,%20Mosul,%20Iraq&rft.date=2023-04&rft.volume=30&rft.issue=2&rft.spage=162&rft.epage=173&rft.pages=162-173&rft.issn=1110-4902&rft.eissn=1110-4902&rft_id=info:doi/10.55133/eji.300215&rft_dat=%3Cproquest_cross%3E2799172877%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2799172877&rft_id=info:pmid/37031465&rfr_iscdi=true